Kura Oncology Inc
0.0 %
-59.63 %
Yet to be announced
Company Overview
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company committed to developing precision medicines for the treatment of cancer. The company's primary focus is on small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
The company's lead drug candidate is ziftomenib (KO-539), an orally bioavailable small molecule inhibitor of the menin-KMT2A protein-protein interaction, which is currently in clinical trials for acute myeloid leukemia (AML). The company also has other pipeline products in development for various cancer indications.
Revenue Sources
Kura Oncology is a pre-revenue clinical-stage biopharmaceutical company focused on developing cancer treatments. As the company is still in the research and development phase without any commercialized products, and therefore no revenue, this criterion is not applicable at this stage of the company's development.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Looking at the last four quarters, the company has reported interest expenses ranging from $394,000 to $412,000 per quarter. However, since the company is pre-revenue and still in research and development phase, the interest expense ratio check is not applicable at this stage of development.
Operational Ethics
Based on review of the company's SEC filings, corporate documentation, and public information, there is no evidence of any significant ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party. The company's operations and clinical trials are primarily conducted in the United States.
Login to join the discussion